‏إظهار الرسائل ذات التسميات UTEC. إظهار كافة الرسائل
‏إظهار الرسائل ذات التسميات UTEC. إظهار كافة الرسائل

Bangalore-based Biopharma Startup Bugworks Raises $7.5 Mn from Japan-based VCs and Acquipharma Holdings

Bugworks Research Inc, a global biopharma start-up designing novel broad-spectrum antibiotics, announced the completion of a $7.5M financing, led by University of Tokyo Edge Capital (UTEC) Japan and Global Brain Corporation (Global Brain) Japan, along with Acquipharma Holdings, South-Africa. The company has raised $19M till date and has 3one4 Capital as an existing investor.

This investment enables Bugworks to complete Phase 1 studies for its GYROX series Intravenous drug candidate and advance an Oral lead towards clinical development. Bugworks' drug candidate, a dual-target gyrase-topoisomerase inhibitor, supported by CARB-X since 2017, is a novel broad-spectrum agent targeting critical bacterial infections implicated in serious hospital, community and biothreat indications.

"UTEC led the Bugworks Series A in 2018, as we identified Antimicrobial resistance (AMR) as one of the global issues of mankind, and facilitated Bugworks' collaboration with Japanese ecosystem. Bugworks has thoroughly impressed us with their scientific rigour, pre-clinical data, business development progress and commitment to saving lives. We are now proud to double-down our investment in Bugworks," said Tomotaka Goji, Managing Partner & President, UTEC.

"As witnessed with COVID-19, infectious diseases are threatening human existence. AMR is a serious issue and Global Brain regards this as a big unmet medical need. We are proud to partner with Bugworks to bring highly differentiated solutions in AMR to the market. We consider India to be an important region, both from innovation and market perspective and are hence accelerating our investment activity in India," said Yasuhiko Yurimoto, Founder-CEO & General Partner Global Brain.

"This new financing is an endorsement of our team and differentiated AMR assets, as we bring reputed global investors to aid our mission of pandemic preparedness by defeating superbug infections," said Dr. Anand Anandkumar, CEO of Bugworks.

Investors Profile

UTEC is a Tokyo-based early-stage VC with over $500M AUM with 11 successful IPOs and 11 M&As. UTEC invests in seed/early-stage startups that solve global issues of humankind using profound science and technology.

Global Brain is a VC firm based in Tokyo with offices in San Francisco, London, Seoul, Singapore and Jakarta. With over $1.5B assets under management, Global Brain has invested in 200+ startups selectively from seed/early to pre-IPO startups and achieved 17 IPOs and 48 M&As.

Acquipharma Holdings is a South-Africa based life-science boutique investment fund, who've invested in Bugworks since 2016.

www.bugworksresearch.com

AI-driven Healthcare Analytics Firm Tricog Raises $10.5 Mn in Series B Funding

Tricog, one of the world’s largest healthcare analytics firms, has raised 10.5 million USD in Series B funding round from UTEC - The University of Tokyo Edge Capital, Japan; Aflac Ventures, LLC, Japan; TeamFund, USA and Dream Incubator, Japan. Existing investors Inventus Capital and Blume Ventures also participated in this round. 

The investment comes two years after Tricog’s Series A funding round, bringing the company’s total funding to 17.5 million USD. Since the previous round, Tricog has grown its presence in over 12 countries in South-East Asia and Africa. Tricog’s AI-powered platform has been used by over 3 million patients globally for wellness, screening and diagnosis of acute as well as chronic heart diseases. 

Founded in 2015 by Dr. Charit Bhograj, Dr. Zainul Charbiwala, Dr. Udayan Dasgupta and Abhinav Gujjar, Tricog leverages its deep medical and technology expertise, to provide Virtual Cardiology Services to remote clinics, powered by ground-breaking AI and medical experts. Tricog’sInstaECG platform has been deployed in over 2,500 Cathlabs, Hospitals, Clinics and Diagnostic Centres to help diagnose and manage patients with critical cardiac diseases including heart attacks. The platform has been deployed across both government and private health care networks and has demonstrated a significant reduction in mortality and morbidity.

Dr. CharitBhograj, CEO & Founder said, “We have witnessed phenomenal growth from our initial investments, both in terms of footprints in new geographies as well as revenue growth. Through this round of investment, we reinforce our commitment to strengthen our AI-powered platform for faster diagnosis, expand our product line and establish strong presence in Africa and Asia including India, China and Japan."

Tricog has recently launched the InstaEcho platform for remote echocardiography with a focus on using AI to enable Point of Care Cardiac Ultrasound for the diagnosis of Heart Failure, Valvular Heart disease and screening for Congenital Heart Disease. Tricog is also awaiting USFDA approval for its proprietary DeepRhythm platform for real-time patient monitoring.

Noriaki Sakamoto, Partner and Board Director, UTEC, Japan said: “Tricog is a shining illustration of a multidisciplinary deep-technology innovation originating in Asia while solving a large global unmet need.  As the lead investors of their Series A round in 2018, we were especially impressed with their scientific rigor, exemplary leadership, revenue prospects and commitment to saving lives. We are now proud to lead their Series B as well, and supplement Tricog with Japanese medical device partnerships and R&D collaborations."

Inventus Capital and Blume Ventures are the earliest investors in Tricog. ParagDhol, Director, Inventus Capital, said  “The Tricog team is amongst the most well-rounded we have backed. It is a privilege to have a ringside seat as Dr. Charit, Zainul, Udayan and Abhinav build out a classy healthcare technology company."

Sanjay Nath, Managing Partner at Blume Ventures, quoted “We’ve seen Tricog’s evolution from an India-based ECG healthcare startup to an integrated, AI-driven full-stack ‘virtual cardiologist’ platform. Most Indian B2B startups have traditionally focused on Enterprise/SaaS.  We’re proud to see DrCharit and the co-founding team at Tricog lead the way in building out deep-tech innovation, expanding product lines and creating impact by saving lives across developing markets globally".

YousufMazhar, Partner at TeamFund, an impact focused fund based in the US, said: “Tricog’s solution in low resource settings is a game changer by allowing not only instant ECG and Echo readings without a Cardiologist present, but also the ability to immediately detect life threatening situations such as heart attacks, allowing appropriate care to be administered in a timely manner."

Managing Director, Tomoyuki Shimada, Aflac Innovation Partners G.K. Japan, said, “It is an honor for Aflac Ventures, LLC. to invest in Tricog, an excellent professional team. We believe Tricog's approach using ECG plus AI should have a huge impact on our healthcare experience. As an insurance company, Aflac will seek possibilities collaborating with the Tricog team to achieve their mission and try to create opportunities in improving people's quality of life."

Market Reports

Market Report & Surveys
IndianWeb2.com © all rights reserved